EUVIMEDEUVIMED entdecken
Open Access

Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma

Alicia Eckhardt, Richard Drexler iD, Melanie Schoof, Nina Struve, David Capper iD, Claudius Jelgersma, Julia Onken, Patrick N Harter, Katharina J Weber, Iris Divé, Kai Rothkamm, Konstantin Hoffer und 6 weitere

Neuro-Oncology · 04.03.2024 · 26 (3) · 503-513

DOI: 10.1093/neuonc/noad197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.10.2023. Verfasst von Alicia Eckhardt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy & Radiation Oncology, Hubertus Wald Tumor Center - University Cancer Center Hamburg, University Medical Center Hamburg-Epp…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Landesforschungsförderung Hamburg, Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The IDH-wildtype glioblastoma (GBM) patients have a devastating prognosis. Here, we analyzed the potential prognostic value of global DNA methylation of the tumors.

Methods

DNA methylation of 492 primary samples and 31 relapsed samples, each treated with combination therapy, and of 148 primary samples treated with radiation alone were compared with patient survival. We determined the mean methylation values and estimated the immune cell infiltration from the methylation data. Moreover, the mean global DNA methylation of 23 GBM cell lines was profiled and correlated to their cellular radiosensitivity as measured by colony formation assay.

Results

High mean DNA methylation levels correlated with improved survival, which was independent from known risk factors (MGMT promoter methylation, age, extent of resection; P = 0.009) and methylation subgroups. Notably, this correlation was also independent of immune cell infiltration, as higher number of immune cells indeed was associated with significantly better OS but lower mean methylation. Radiosensitive GBM cell lines had a significantly higher mean methylation than resistant lines (P = 0.007), and improved OS of patients treated with radiotherapy alone was also associated with higher DNA methylation (P = 0.002). Furthermore, specimens of relapsed GBM revealed a significantly lower mean DNA methylation compared to the matching primary tumor samples (P = 0.041).

Conclusions

Our results indicate that mean global DNA methylation is independently associated with outcome in glioblastoma. The data also suggest that a higher DNA methylation is associated with better radiotherapy response and less aggressive phenotype, both of which presumably contribute to the observed correlation with OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansPrognosisDNA MethylationDNA Modification MethylasesTumor Suppressor ProteinsBiomarkers, TumorDNA Repair Enzymes

Stichwörter der Autor:innen

DNA methylationglioblastomaoverall survivalradiotherapy response

Substanzen

DNA Modification MethylasesTumor Suppressor ProteinsBiomarkers, TumorDNA Repair Enzymes

Autor:innen und Institutionen

  • Department of Radiotherapy & Radiation Oncology, Hubertus Wald Tumor Center - University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.
  • Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Mildred-Scheel Cancer Career Center HATRICs4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Richard Drexler, David Capper, Franz Ricklefs, Ulrich Schüller

Förderung

  • Landesforschungsförderung Hamburg
  • Deutsche Krebshilfe

Zitieren

APA

Eckhardt, A., Drexler, R., Schoof, M., Struve, N., Capper, D., Jelgersma, C., Onken, J., Harter, P. N., Weber, K. J., Divé, I., Rothkamm, K., Hoffer, K., Klumpp, L., Ganser, K., Petersen, C., Ricklefs, F., Kriegs, M., & Schüller, U. (2024). Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma. Neuro-Oncology, 26(3), 503-513. https://doi.org/10.1093/neuonc/noad197

Vancouver

Eckhardt A, Drexler R, Schoof M, Struve N, Capper D, Jelgersma C, et al. Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma. Neuro-Oncology. 2024;26(3):503-513. doi:10.1093/neuonc/noad197

BibTeX
@article{Eckhardt2024,
  author = {Eckhardt, Alicia and Drexler, Richard and Schoof, Melanie and Struve, Nina and Capper, David and Jelgersma, Claudius and Onken, Julia and Harter, Patrick N and Weber, Katharina J and Divé, Iris and Rothkamm, Kai and Hoffer, Konstantin and Klumpp, Lukas and Ganser, Katrin and Petersen, Cordula and Ricklefs, Franz and Kriegs, Malte and Schüller, Ulrich},
  title = {Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {3},
  pages = {503--513},
  doi = {10.1093/neuonc/noad197}
}
Kostenlos starten →